Trial
NCT01558115
Denosumab in Primary Hyperparathyroidism
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Columbia University
Collaborators
National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Amgen
Condition
Primary Hyperparathyroidism
Intervention
Denosumab
Why stopped
Poor enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-02